Coherus Oncology, Inc. (CHRS)
1.41
-0.05
(-3.42%)
USD |
NASDAQ |
Aug 28, 16:00
1.40
-0.01
(-0.71%)
After-Hours: 20:00
Coherus Oncology Enterprise Value : 166.67M for Aug. 28, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 28, 2026 | 166.67M |
| August 27, 2026 | 174.40M |
| August 26, 2026 | 172.85M |
| August 25, 2026 | 160.50M |
| August 24, 2026 | 158.95M |
| August 21, 2026 | 168.22M |
| August 20, 2026 | 152.77M |
| August 19, 2026 | 154.32M |
| August 18, 2026 | 155.86M |
| August 17, 2026 | 126.51M |
| August 14, 2026 | 134.24M |
| August 13, 2026 | 124.97M |
| August 12, 2026 | 129.60M |
| August 11, 2026 | 135.78M |
| August 10, 2026 | 140.41M |
| August 07, 2026 | 145.05M |
| August 06, 2026 | 144.28M |
| August 05, 2026 | 172.85M |
| August 04, 2026 | 177.49M |
| August 03, 2026 | 171.31M |
| July 31, 2026 | 166.67M |
| July 30, 2026 | 175.94M |
| July 29, 2026 | 166.67M |
| July 28, 2026 | 171.31M |
| July 27, 2026 | 174.40M |
| Date | Value |
|---|---|
| July 24, 2026 | 166.67M |
| July 23, 2026 | 169.76M |
| July 22, 2026 | 169.76M |
| July 21, 2026 | 175.94M |
| July 20, 2026 | 168.22M |
| July 17, 2026 | 165.13M |
| July 16, 2026 | 163.58M |
| July 15, 2026 | 171.31M |
| July 14, 2026 | 172.85M |
| July 13, 2026 | 175.94M |
| July 10, 2026 | 186.76M |
| July 09, 2026 | 200.66M |
| July 08, 2026 | 203.75M |
| July 07, 2026 | 206.84M |
| July 06, 2026 | 189.84M |
| July 02, 2026 | 172.85M |
| July 01, 2026 | 171.31M |
| June 30, 2026 | 165.13M |
| June 29, 2026 | 110.94M |
| June 26, 2026 | 118.65M |
| June 25, 2026 | 115.57M |
| June 24, 2026 | 121.73M |
| June 23, 2026 | 112.48M |
| June 22, 2026 | 115.57M |
| June 18, 2026 | 115.57M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Enanta Pharmaceuticals, Inc. | 388.57M |
| ACADIA Pharmaceuticals, Inc. | 4.128B |
| Alnylam Pharmaceuticals, Inc. | 31.39B |
| Anika Therapeutics, Inc. | 269.22M |
| Savara, Inc. | 937.77M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -33.35M |
| Revenue (Quarterly) | 14.31M |
| Total Expenses (Quarterly) | 47.65M |
| EPS Diluted (Quarterly) | -0.1312 |
| Gross Profit Margin (Quarterly) | 64.33% |
| Profit Margin (Quarterly) | -233.1% |
| Earnings Yield | -72.43% |
| Normalized Earnings Yield | -71.52 |